Aruna Pradhan, MD

Adjunct Assistant Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

An associate epidemiologist, cardiologist, and Assistant Professor of Medicine at Harvard Medical School, Dr. Pradhan joined CIRT in 2005. She has joint appointments in the Division of Preventive Medicine at the Brigham and Women’s Hospital and Cardiovascular Medicine Division at the Veteran’s Administration Hospital, West Roxbury Campus. Her research interests span the related areas of inflammation, diabetes, and peripheral artery disease. Her early work demonstrated a strong link between subclinical inflammation and the development of diabetes. She continued this line of research as the Principal Investigator of the LANCET clinical trial which studied insulin therapy as a strategy to reduce inflammation among patients with diabetes during the initial stage of this disease. Other research activities pertain to the role of adipokines and other biologic markers having combined metabolic and inflammatory functions in the pathogenesis of diabetes and its vascular complications. As a recipient of a career development award from the National Heart, Lung, and Blood Institute to study risk factors for peripheral artery disease, Dr. Pradhan is also keenly interested in evaluating risk factors and underlying mechanisms that distinguish individuals at high risk for future coronary artery disease as compared to lower extremity artery disease. Dr. Pradhan is also a recipient of NIH funding to evaluate mechanisms of statin-associated diabetes in the JUPITER trial.

Dr. Pradhan completed her cardiovascular medicine fellowship at the Brigham and Women’s Hospital and continues her clinical activities as an echocardiographer and clinical cardiologist at the VA Boston Healthcare System, West Roxbury Campus.

Publications

  • Published 12/19/2025

    Turner ME, Nakamura Y, Tanaka T, Blaser MC, Kasai T, Lupieri A, Itoh S, Ge R, Perez KA, Itagawa R, Weiss L, Okui T, Sasaki Y, Pradhan AD, Libby P, Ridker PM, Singh SA, Aikawa M, Aikawa E. Selective PPAR-a activation with pemafibrate attenuates macrophage-mediated progression of calcific aortic valve disease. bioRxiv. 2025 Dec 19. PMID: 41446100.

    Read at: PubMed

  • Published 9/5/2025

    Duran EK, Cook NR, Aday AW, Buring JE, Ridker PM, Pradhan AD. Unsupervised Learning Analysis of Triglycerides, Inflammation, Cholesterol, and the Risks of Incident Cardiovascular Disease and Type 2 Diabetes in the Women's Health Study. J Am Heart Assoc. 2025 Sep 16; 14(18):e039381. PMID: 40913283.

    Read at: PubMed

  • Published 5/14/2025

    Nordestgaard AT, Pradhan AD, Everett BM, MacFadyen JG, Bhatt DL, Visseren FLJ, Libby P, Santos RD, Nissen SE, Nordestgaard BG, Ridker PM. Expanding the triglyceride range in clinical trials: therapeutic opportunities. Eur Heart J. 2025 May 14; 46(19):1835-1848. PMID: 39950981.

    Read at: PubMed

  • Published 4/8/2025

    Tobias DK, Pradhan AD, Duran EK, Li C, Song Y, Buring JE, Cook NR, Mora S, Manson JE. Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial. Nat Commun. 2025 Apr 08; 16(1):3332. PMID: 40199888.

    Read at: PubMed

  • Published 11/2/2024

    Qian F, Guo Y, Li C, Liu Y, Luttmann-Gibson H, Gomelskaya N, Demler OV, Cook NR, Lee IM, Buring JE, Larsen J, Boring J, McPhaul MJ, Manson JE, Pradhan AD, Mora S. Biomarkers of glucose-insulin homeostasis and incident type 2 diabetes and cardiovascular disease: results from the Vitamin D and Omega-3 trial. Cardiovasc Diabetol. 2024 Nov 02; 23(1):393. PMID: 39488682.

    Read at: PubMed

View All 69 Publications:   View Full Profile in BUMC

Websites

Education

  • Georgetown University School of Medicine, MD
  • Harvard School of Public Health, MSc
  • Johns Hopkins University School of Public Health, MPH
  • Georgetown University, BS

View all profiles